Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PTC Therapeutics -- PTCT -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (16)	10/7/2014 11:35:24 AM
From: ghmm	Read Replies (1) \| Respond to of 38

Martin is a smart guy (much more than me) and seems to know his stuff well. He has certainly been right more often than not in his short thesis. That being said I recall his short case for NKTR proved to be wrong on multiple fronts (naloxegol, price targets, accounting for royalties and rest of NKTR pipeline in valuation). I tended to agree with him on 102 (I think it has a chance I just didn't like NKTR spending all the cash to find out). On PTC I don't have a position because I am just not sure on their DMD drug. I wonder if like NKTR though he isn't putting any value on their other candidates. I saw a tweet where it seemed to imply the SMA had little value since it was in Roche's hands. I like royalties so to me it could be quite valuable.